News

Ultomiris (ravulizumab) has been approved in the European Union for expanded use to include children (with a body weight of 10 kg or above) and adolescents with paroxysmal nocturnal…
Read More...

Sorrento Therapeutics, Inc. announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering…
Read More...

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced it has completed the transaction to acquire LakePharma Inc., a privately held…
Read More...

Agilent Technologies Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial…
Read More...

Entos Pharmaceuticals (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, is…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced it has initiated its submission to the U.S. Food and Drug Administration (FDA)…
Read More...

Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA…
Read More...

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced it has initiated its submission to the U.S. Food and Drug Administration (FDA)…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell announced that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone…
Read More...

Senhwa Biosciences, Inc. a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that its oral new drug,…
Read More...

Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced new data from multiple clinical studies that demonstrate improvements in chronic…
Read More...

Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S. Food and Drug Administration…
Read More...

UCB announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BRIVIACT (brivaracetam) CV tablets, oral solution, and injection to treat…
Read More...

Roche announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane,…
Read More...

Novartis announced that the European Commission (EC) has granted orphan drug designation to sabatolimab (MBG453) for the treatment of myelodysplastic syndromes (MDS), based on clinical…
Read More...

Novartis  announced results from two pooled post hoc analyses of Phase III ORION-9, -10 and -11 trials that showed twice-yearly Leqvio (inclisiran) provided effective and sustained…
Read More...

BioMarin Pharmaceutical Inc. announced that the European Commission (EC) has granted marketing authorization for VOXZOGO (vosoritide), a once daily injection to treat achondroplasia in…
Read More...

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with…
Read More...